Questions regarding the appropriate therapy for syphilis remain, despite the many years during which this infection has been subjected to intense scientifi scrutiny. In an effort to provide guidance for the development of the 1998 sexually transmitted disease (STD) treatment guidelines of the Centers for Disease Control and Prevention (CDC), these questions were outlined and an effort to answer them was made. Articles relating to syphilis treatment published after the previous revision of the CDC STD treatment guidelines (in 1993) and by the end of 1996 were identifie with use of MEDLINE. Abstracts from relevant scientifi meetings held during that time were also examined. Reference was also made to older literature, and expert opinion was sought. Conclusions were reached and recommendations were made on the basis of published evidence wherever possible.
A randomly selected 6-month index of the Journal of the Methods American Medical Association from the turn of the century A computerized search on MEDLINE was conducted for contained nearly 40 entries relating specifically to syphilis, far articles published from 1993 (the time of the last comprehenmore than heart disease and cirrhosis entries combined [1] .
sive analysis) through the end of 1996 that related to the natural More recently, in 1995, the Index Medicus listed Ç150 referhistory and treatment of syphilis (table 1) . In addition, abstracts ences to syphilis [2] . Yet, despite the scrutiny to which syphilis relevant to syphilis treatment that were presented at an Interscihas been subjected, both its natural history and the optimal ence Conference on Antimicrobial Agents and Chemotherapy, therapeutic approach continue to defy precise description. In
International Symposium of Sexually Transmitted Diseases, or the current era, HIV infection has, to a certain extent, underInternational AIDS Meeting during the period of 1993 -1996 mined the assumed validity of our models of syphilis staging were also examined. Data from a CDC-sponsored multicenter and of our understanding of the clinical and serological retrial published in mid-1997 were included [7] . sponse to therapy.
With use of these references as well as the comprehensive The Centers for Disease Control and Prevention (CDC) has review by Rolfs prepared for the 1993 guidelines revision [20] , grappled with some of these issues by periodically (in 1982, a series of questions was formulated that addressed the central 1985, 1989 , and 1993) providing guidelines for the treatment and often ambiguous areas of syphilis management. In both of syphilis, as part of its comprehensive Sexually Transmitted the formulation of those questions and the effort to answer Diseases (STD) Treatment Guidelines [3 -6] . Recognizing that them, the opinions of investigators with recognized expertise the state of knowledge of STDs is constantly changing, the and interest in syphilis were solicited [21] . Where necessary, CDC initiated a revision of those guidelines in 1997. Specialists reference was made to older literature. with interest and expertise in each of the specific STDs under consideration were asked to prepare analyses of the current Questions and Review of the Evidence literature. These were presented for review to CDC staff members, who offered critiques of the presentation and analysis. A in making conclusions and finalizing recommendations. These Long-acting preparations of penicillin, such as intramuscular recommendations were then presented to all conference particibenzathine penicillin G (2.4 million units), have been recompants for final comment. This article examines the data from mended for several decades for the treatment of early stage which current guideline recommendations and revisions for the syphilis [22 -24] . Although the studies that led to their recomtreatment of syphilis in nonpregnant adults arose. mendation were problematic because of the nonrandom allocation of patients and a lack of uniform outcomes, 40 years' clinical experience supports the contention that with regard stage syphilis, compliance with such a complex oral regimen for 10 days is problematic. million units intramuscularly, given once) to the same regimen plus 2 g of amoxicillin and 500 mg of probenecid (orally three Ceftriaxone has been repeatedly presented as a possible alternative to penicillin in early stage disease [27] . Unfortunately, times daily for 10 days) for 553 HIV-seropositive and HIVseronegative patients with primary, secondary, or early latent no data have been contributed to the medical literature since the last revision of the CDC STD Treatment Guidelines in syphilis [7] . Slightly more than 50% of patients were available for follow-up through 6 months and 12 months.
1993 that either support or refute this drug's role in this circumstance. The proper dose, duration, and efficacy of ceftriaxone There was only one reported clinical failure, involving an HIV-seropositive patient who received standard therapy. Aptherapy for early syphilis have not been definitively established.
On the basis of pharmacokinetics alone, single-dose ceftriaxone proximately 15% of patients who received treatment with either regimen failed to meet the standard criterion for serological cannot be expected to provide adequate therapy for early syphilis [20] . Therefore, if the clinician decides to use ceftriaxone success (a decrease in the nontreponemal serological titer by two dilutions) by as late as 12 months. HIV-seropositive enrolldespite the limited evidence, regimens of at least 5 -7 days would seem prudent. ees with primary syphilis were statistically more likely than their HIV-seronegative counterparts to have this serological
The azalide antibiotic azithromycin has many properties that suggest it might be useful as therapy for early stage syphilis. characteristic.
In the relatively short follow-up period of that study, none of It is active against Treponema pallidum in vitro and has been effective in experimental models of syphilis [28, 29] . Although the HIV-seropositive patients experienced the type of dramatic treatment failure that has been reported anecdotally over the plasma concentration of azithromycin may be nearly unmeasurable, high levels are achievable in tissue. The half-life of the past 10 years. Since it is unclear (in this instance) that serological failure clearly correlates with clinical failure and in the drug is extremely long, and this makes it ideal as therapy against T. pallidum, an organism with a prolonged doubling absence of any data supporting a more effective therapy, it seems warranted to continue use of the recommended treatment time [30] . Verdon and colleagues treated 16 patients with early stage regimen (2.4 million units of benzathine penicillin G intramuscularly) for early syphilis, irrespective of HIV serostatus.
syphilis with azithromycin (500 mg orally once daily for 10 days) [11] . Compliance with this regimen was good. Clinical cure was documented for 11 of 13 patients who had ú3 or the patient may have been reinfected, while another, deRolfs et al. [7] examined high-dose amoxicillin in combinaspite declining serological titers, did not serorevert. Other, tion with probenecid vs. the standard dose of penicillin as ongoing studies suggest this antibiotic may be useful for early therapy for early syphilis. This oral regimen was selected for stage syphilis and may also be efficacious as a single-dose its potential to achieve treponemacidal levels in the CSF, not in preventing incubating syphilis among patients treated for considered possible with the standard regimen [25, 26] patients have been studied for a general recommendation to While use of 2.4 million units of benzathine penicillin G every week for 3 weeks does not achieve treponemacidal levels be made regarding the use of azithromycin in the treatment of syphilis.
in the CSF, in the pre-HIV era this regimen appeared to be effective in preventing progression of disease. Few instances of neurosyphilis following this therapy were ever noted [32] . The explanation for this seeming contradiction was that an
Should the ''Early Latent'' Designation Be Maintained?
intact immune system played an important role in disease conSerological evidence of syphilis in the absence of clinical trol in the CNS. An incompetent immune response then became signs or symptoms is referred to as latent-stage disease. Early the convenient explanation for the sudden flurry of reports in latency has been classically defined as the period of latency the mid-to late 1980s of HIV-seropositive patients developing during which symptoms of secondary disease might recur. Clin-CNS complications from syphilis despite the receipt of standard ical experience and the recent study of Rolfs et al. suggest therapy for early stage disease [33, 34] . that a single intramuscular injection of 2.4 million units of These reports appeared to suggest that recommended therabenzathine penicillin G is adequate therapy for this stage of pies for syphilis were more likely to fail for HIV-infected disease [7] . For patients in whom early latent disease can be patients than for non-HIV-infected patients. However, no wellaccurately diagnosed, on the basis of either recent serological done comparative study has supported this assertion. The maconversion or recent exposure to an infectious individual, no jority of HIV-infected patients appear to respond appropriately current data suggest that additional therapy beyond the curto recommended therapies. The true nature and magnitude of rently recommended regimen is necessary. Since treatment for the risk HIV infection imparts on the natural history and reearly latent and late latent stages differ, the designation of the sponse to therapy for syphilis have not yet been adequately former remains useful.
documented.
In the time since the last revision of the STD treatment guidelines, no substantive data have been published that shed light on from among ú1,200 HIV-infected U.S. Navy personnel [18] . CSF evaluation and follow-up data were available for only a small The adequacy of three weekly intramuscular injections of benzathine penicillin G for the treatment of latent syphilis has subset of this group, and treatment regimens differed. Relapses, mostly serological, were noted among small numbers of patients never been adequately studied. Although it is difficult to ascertain the optimal treatment regimen on the basis of the medical with early and latent-stage syphilis. Goeman et al. examined the serological response to therapy literature, two pathological aspects of disease that appear to differ in early and latent stages of syphilis have been considered in patients with syphilis in a nested cohort of female sex workers enrolled in a cross-sectional study of STD prevalence in important in the devising of strategies. First, spirochetes probably divide more slowly in latent-stage disease than in early Kinshasa, Zaire [10] . Though it was not explicitly stated in the article, most of the subjects probably had latent-stage syphilis, stage disease. It has been inferred that eliminating T. pallidum in late latent syphilis requires longer exposure to effective as few cases of symptomatic disease were noted. Serological responses among HIV-infected and non-HIV-infected women antibiotics than might be needed in early stage syphilis. Sequential dosing with intramuscular benzathine penicillin prowere similar. No indication of clinical relapse following standard penicillin therapy was noted. Gourevitch and colleagues vides continuous low levels of penicillin for 3 -4 weeks.
Second, the goal of therapy for latent-stage disease is primarstudied a small cohort of patients with latent syphilis enrolled in a methadone maintenance program in New York City [14] . ily to eliminate the risk of progression to end-organ damage in the host and not, as in the case of early syphilis, the resolution In 11 months of follow-up there appeared to be no difference in the rate of acceptable serological responses to standard therapy of infectious lesions. Although this goal is easily achieved in most patients with standard therapy, it is potentially complibetween HIV-infected and non-HIV-infected patients.
In the final analysis, there is no indication from the literature cated by the sequestration of organisms in areas inaccessible to adequate levels of antibiotics, such as the CNS. Invasion of that three weekly injections of benzathine penicillin is inadequate for truly latent syphilis. Nor is there any indication that the CNS by spirochetes occurs frequently and early in the natural history of syphilis [31] , but whether and in what circumthe regimen is inadequate when the patient is concurrently infected with HIV and does not have asymptomatic neurosyphstances this leads to progression to neurosyphilis has never been clearly defined. Most patients in whom CNS invasion ilis (see below). tion not responsive to standard therapy, warrants the same secondary-stage syphilis [31] . This has never been shown to diagnostic evaluation. The necessity for lumbar puncture in predict progression to neurological complications. Rolfs et al.
patients with latent disease and a nontreponemal serological did not demonstrate that CSF abnormalities in early stage syphtest (NTST) titer of §1:32 is unproven, although some studies ilis, although common, were predictive of treatment failure [7] .
have suggested that patients with neurosyphilis tend to have CSF abnormalities have also been shown to be common in high NTST titers [40] . The prevalence of neurosyphilis in the HIV infection in the absence of any discernible pathogen, expopulation of patients with latent syphilis and titers of §1:32 cept perhaps HIV, and are generally not considered predictive has never been determined. In a study of a small cohort of of neurological sequelae [35] .
patients, Carey et al. were unable to demonstrate a correlation The poor predictive value of CSF abnormalities in early between an NTST titer exceeding 1:32 and CSF abnormalities stage syphilis with or without HIV infection cannot justify suggestive of neurosyphilis among either HIV-seropositive or routine lumbar punctures for this patient population. In this HIV-seronegative patients with latent-stage syphilis [12] . setting, CSF evaluation should be reserved for cases of serolog-
The recommendation that evaluation of CSF precede nonical and clinical failure or for those with concomitant neurologipenicillin therapy for patients with latent syphilis was based cal or ocular symptoms. No recent studies have found otheron the concern that these therapies (i.e., with tetracyclines and wise.
macrolides) had no documented or theoretical efficacy against The necessity of CSF evaluation in certain cases of latentneurosyphilis (unlike a regimen of 7.2 million units of benzastage syphilis is compelling. For many years, a regimen of thine penicillin G intramuscularly, which clinicians' experience three weekly intramuscular injections of 2.4 million units of showed was effective for curing many cases of asymptomatic benzathine penicillin G was considered appropriate and adeneurosyphilis). The planned use of a particular therapy is not quate therapy for neurosyphilis, thereby providing a measure predictive of asymptomatic neurosyphilis. Therefore, it is difof security for those receiving treatment for latent disease who ficult to justify a lumbar puncture for every patient with latent had documented or unappreciated asymptomatic neurosyphilis.
syphilis that warrants nonpenicillin therapy. The failure to demonstrate treponemacidal levels of penicillin For patients with latent syphilis and underlying HIV infecin the CSF after administration of benzathine penicillin, as well tion, it still seems prudent to recommend a CSF evaluation. as anecdotal reports of failure of this regimen, led to the adopData culled from more than one recent study suggest that at tion of a more aggressive approach consisting of intravenous least 10% of HIV-seropositive patients with latent disease will aqueous penicillin G or intramuscular procaine penicillin for have a reactive CSF-VDRL, a specific marker for neurosyphilis 10 -14 days for treatment of symptomatic or asymptomatic [15, 18, 41] . Whether or not risk can be further stratified by neurosyphilis [32, 36, 37] .
other clinical indicators such as CD4 cell count or the height The suggestion that therapy for latent syphilis was not adeof the NTST titer remains to be demonstrated. quate for neurosyphilis posed a diagnostic dilemma. In distinction to early stage syphilis, CSF abnormalities in latent-stage disease have been considered more predictive of progression to neurological complications [38] . It therefore became necessary, for therapeutic purposes, to identify any patient with latent Assessing the efficacy of therapies for the various stages disease who had asymptomatic neurosyphilis. This could be of syphilis is complicated by the lack of a clearly defined, done only by lumbar puncture and CSF evaluation. Unfortuconsistently observed marker of response. Failure of therapy, nately, this was not practical for many facilities offering care as demonstrated by recurrence, persistence, or progression of for syphilis. Widely applied, this strategy wasn't clearly costsymptoms or by a rising titer, is a dramatic but rare event. effective either [39] .
Unfortunately, the absence of these findings does not guarantee Risk factors that could be used to predict which patients microbiological cure or the prevention of long-term sequelae. with latent syphilis might also have asymptomatic neurosyphWithout the ability to establish the elimination of a causative ilis would be considered valuable clinical tools. The 1993 CDC organism as a criterion for cure, the clinician is left to follow treatment guidelines recommended lumbar puncture and CSF the rise and fall of the NTST titer to determine if therapy has examination be performed for patients with late latent syphilis been successful. The 1993 STD treatment guidelines specified that the absons for the substitution of intravenous therapy have been discussed above. It was also considered appropriate to treat neurosence of a fourfold decline in titer 3 months after therapy for primary or secondary disease identifies individuals at risk for syphilis with 600,000 units of intramuscular procaine penicillin G (without probenecid) daily for 10 days. As in the case of treatment failure. That recommendation was based on data from a reanalysis of an earlier study in which the endpoint was weekly benzathine penicillin, this regimen fell out of favor as therapy for neurosyphilis after a small number of reports retreatment. The criteria for retreatment in that earlier study were poorly defined [42, 43] . Subsequent studies have consissuggested that the disease progressed in some patients with symptomatic neurosyphilis and that CSF abnormalities failed tently demonstrated that anywhere from 15% to 25% of patients will not have a fourfold decrease in titer over the 3-month to resolve with this treatment regimen [45, 46] . One study documented that levels of penicillin in the CSF 3 hours after period and may in fact not have such a drop over a period extended to 6 months or beyond [7, 44] . To date, no study has intramuscular administration of 600,000 units of procaine penicillin G were below the detectable limits of the bioassay and documented that these patients are at risk for progression of disease.
were considered nontreponemacidal [47] .
The adequacy or inadequacy of these older regimens has not While it seems prudent to monitor patients clinically and serologically for an extended period of time, there is no clear been properly addressed by any recent study. Some experts argue that the studies which resulted in the abandonment of evidence that they should receive additional courses of therapy or undergo invasive diagnostic studies (i.e., lumbar puncture) the older treatment regimens for neurosyphilis are difficult to interpret and don't necessarily apply to patients with asympwithin 3 months after therapy if the NTST titer fails to decline fourfold. The frequency of serological follow-up for nonimmutomatic neurosyphilis, particularly non-HIV-infected individuals. A number of studies have suggested that even high-dose nocompromised patients with early stage disease can probably be safely reduced to 6-month intervals.
intravenous penicillin may not reliably cure all neurosyphilis. In a small observational study, Gordon and colleagues reThe serological assessment of response to therapy in patients with latent-stage syphilis is even more problematic than ported that three of seven HIV-seropositive patients failed to respond appropriately to high-dose penicillin therapy for neuroit is for those with early stage disease. Few studies have offered guidance on this matter. In one recent study, Ç30%
syphilis [8] . Malone et al. reported that 70% of HIV-seropositive patients treated with high-dose penicillin suffered a seroof HIV-seronegative patients with latent syphilis had not had a fourfold drop in the NTST titer by 12 months after therapy logical relapse, and among these were patients with documented neurosyphilis [18] . The number of patients studied [10] . On the contrary, Malone et al. found that of those patients followed-up, 100% of those with early latent disease and in either case was small, and no comparisons with HIV-seronegative patients were made. 95% of those with late latent disease had a fourfold decrease in titer by 12 months [18] .
Marra and colleagues reported on serial CSF studies in a group of HIV-infected and non-HIV-infected patients with neuAccording to the 1993 CDC STD treatment guidelines, rising titers or the development of clinical symptoms after therapy rosyphilis following CDC-recommended therapy [9] . The CSF-VDRL titer decline appeared to be slower in HIV-seropositive indicated treatment failure. The finding of initially high titers of §1:32 that failed to decline by 12 -24 months after therapy patients than in their HIV-seronegative counterparts. The clinical importance of this finding is unclear. Optimal therapy for was also recommended as a criterion for identifying patients who require evaluation for neurosyphilis and retreatment as neurosyphilis, in terms of either duration or dosage, has not been defined. At the very least the data suggest that patients necessary. In the absence of any substantive data to either refute or support these recommendations, they should be regarded as treated for neurosyphilis, especially HIV-seropositive ones, should be followed closely and undergo repeated CSF evaluareasonable practice.
tion after completing therapy. Repeated courses of therapy should be considered if clinical,
What is Appropriate Therapy for Neurosyphilis?
serological, or other markers of disease fail to resolve after the period of time designated in the current treatment guidelines. The regimen recommended for neurosyphilis in the 1998 STD treatment guidelines is 18 -24 million units of aqueous It is also prudent that the total dosage of daily intravenous penicillin be restricted to the upper range of the standard regipenicillin G intravenously for 10 -14 days. An alternative is 2.4 million units of procaine penicillin G intramuscularly daily men (i.e., 18 -24 MU) to avoid confusion and give patients as much medication as is reasonable. Whether asymptomatic with 500 mg of oral probenecid four times daily for 10 -14 days. Either is commonly followed with a regimen of 2.4 milneurosyphilis in non-HIV-infected individuals could be treated with smaller doses of intramuscular procaine penicillin G (i.e., lion units of benzathine penicillin G intramuscularly once a week for 3 weeks, to achieve a prolonged course of therapy 600,000 units to 1.2 million units q.d.) than those currently recommended is unclear. Since untreated neurosyphilis carries appropriate for latent syphilis.
At one time, the latter regimen of benzathine penicillin G the potential for serious consequences and there are no data to support dose reduction, and since the HIV status of patients is was considered adequate as therapy for neurosyphilis. The rea-S27 CID 1999;28 (Suppl 1) Treatment of Syphilis in Nonpregnant Adults often unknown, it seems appropriate to recommend high-dose Our understanding of this complex disease remains imperfect, despite many years of study. At the very least, it can be intravenous or intramuscular therapy for all patients being treated for neurosyphilis.
said that the clinician and patient should cooperate to ensure long-term clinical and serological follow-up and an appropriate There remains a need for effective alternatives to penicillin. The prolonged half-life, adequate CNS penetration, and aderesponse to therapy. quate activity against T. pallidum of ceftriaxone suggest that this drug may be an appropriate candidate for consideration
